Sickle Cell Disease

U.S. FDA approves Exjade for chronic iron overload due to blood transfusions

Published in Blood Weekly, December 1st, 2005

The Sickle Cell Disease Association of America (SCDAA) announced the U.S. Food and Drug Administration (FDA) has approved Exjade, also known as deferasirox, for once-a-day oral treatment of adults and children with chronic iron overload due to blood transfusions.

Because of its convenience and ease of use, the SCDAA believes that the availability of Exjade will present a significant advancement in the treatment of chronic iron overload, and could help many patients who are unable to comply with infusion therapy, or who are not being treated for their iron overload.

This article was prepared by Blood Weekly editors from staff and other reports. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-12-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry